Bruce Dudzik has been named senior director of business development at NanoInk, the company said this week.
Dudzik joins NanoInk from Affymetrix where he served at senior levels of business development. Dudzik also held positions at Amersham, now GE Healthcare, Vysis, now part of Abbott Labs, and Amoco's biotechnology division.
Dudzik received an MBA from DePaul University and holds a BS in biology from the University of Illinois, Urbana-Champaign.
Mark Crane has become vice president of marketing and business development for Gene Logic's preclinical division, the company said last week. Previously, he held positions in sales and marketing at Quest Pharmaceutical Services, MDS Pharma Services, Avantec, and PerkinElmer. At Gene Logic, he will be responsible for sales and marketing of preclinical services to pharmaceutical and biotechnology companies and to government organizations.
Nicholas Ventresca has become corporate senior vice president of information technology as well as chief information officer of Charles River Laboratories, the company said last week. Prior to joining Charles River Labs, Ventresca was vice president in business technology for Pfizer's corporate headquarters in New York and R&D headquarters in New London, Conn.
Last week, Gentris launched its Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene. The controls were isolated from cells collected from individual donors, and sequences were verified by bi-directional sequencing, said Gentris. The method does not introduce artificial DNA sequences into cell lines, so human genomic DNA reference controls most closely mimic the behavior of genomic DNA isolated from human samples, thereby avoiding consistency, consent and supply issues brought about by the practice of using leftover samples, the company said. Each vial contains 10 mL at a concentration of 50 ng/mL. Additional controls are under development for other important genes including 2C9, 2C19 and UGT1A1, the company added.